N
New Enterprise Associates, Inc.
+ HoldingSNTI
+13.59%
3M Return
$0.340
-0.034 (-10.12%)At close
Loading chart…
- High
- 0.380
- Open
- 0.380
- VWAP
- 0.35
- Vol
- 72.32K
- Mkt Cap
- 14.60M
- Low
- 0.340
- Amount
- 25.55K
- EV/EBITDA, TTM
- -0.69
Senti Biosciences Holdings, Inc. is a wholly owned subsidiary of Senti Holdings, Inc. Senti Biosciences, Inc. is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidate, SENTI-202, is a potentially first-in-class Logic Gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers currently being studied in an open-label, multi-center Phase I clinical trial for the treatment of relapsed/refractory hematological malignancies, including Acute Myeloid Leukemia.
AI analysis of Senti Biosciences Holdings Inc (SNTI)
sellSenti Biosciences Inc is not a good buy right now due to significant financial losses and declining cash reserves. The current price is $0.38, and the company reported a net income loss of $42.21 million in Q1 2026, indicating severe operational challenges. Furthermore, the RSI is at 38.22, suggesting the stock is nearing oversold territory but lacks positive momentum for recovery.
Valuation Metrics
The current forward P/E ratio for Senti Biosciences Holdings Inc (SNTI) is 0.00, compared to its 5-year average forward P/E of -1.18.
Whales holding SNTI
Events Timeline
News
8.507-15seekingalphaSenti Biosciences to be Acquired by Celadon Affiliates, Focusing on New Technology
8.507-15NewsfilterSenti Biosciences Advances Controllable Cell and Gene Therapies
- 9.505-14seekingalpha
Senti Biosciences Reports Q1 2026 Financial Results
- 8.505-14Newsfilter
Senti Bio Advances SENTI-202 Registrational Trial Following FDA Meeting
- 9.503-27seekingalpha
Senti Biosciences Reports Q4 Losses, Misses EPS Estimates
SNTI FAQ — answered by Alphio AI
Senti Biosciences Holdings, Inc. is a wholly owned subsidiary of Senti Holdings, Inc. Senti Biosciences, Inc. is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidate, SENTI-202, is a potentially first-in-class Logic Gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers currently being studied in an open-label, multi-center Phase I clinical trial for the treatment of relapsed/refractory hematological malignancies, including Acute Myeloid Leukemia. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Senti Biosciences Inc is not a good buy right now due to significant financial losses and declining cash reserves. The current price is $0.38, and the company reported a net income loss of $42.21 million in Q1 2026, indicating severe operational challenges. Furthermore, the RSI is at 38.22, suggesting the stock is nearing oversold territory but lacks positive momentum for recovery.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.